Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Martyn D Greenacre is Director at Curis. OQRO lists 1 transaction filed with the SEC under this name, the latest on Jul 9, 2026, each linked to the official Form 4.
Director
Disclosures on record
1
Companies involved
1
CurisCRIS
Jul 7, 20266,800disclosed Jul 9
DetailsOfficial recordMartyn D Greenacre bought shares on the open market in 2012, and has not bought since 2012 across 2 companies. Sales in 4 of the 15 years since 2012.
Martyn D Greenacre reported 1 open-market purchase and 6 sales since 2012; purchases in 2012.
| Year | Bought | Sold |
|---|---|---|
| 2019 | — | $19K1×1 trade |
| 2016 | — | $25K2×2 trades |
| 2013 | — | $220K1×1 trade |
| 2012 | —1×1 trade | $609K2×2 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Martyn D Greenacre bought shares on the open market in 2012, and has not bought since 2012 across 2 companies. Sales in 4 of the 15 years since 2012.
In SEC filings since 2012: the latest open-market purchase is from 2012; the latest open-market sale is from 2019.
2 companies: Curis (CRIS, 2012–2019), Lisata Therapeutics (LSTA, 2012).
Martyn D Greenacre reported 0 open-market purchases and 6 sales here, 2012 to 2019.
Martyn D Greenacre reported 1 open-market purchase and 0 sales here, 2012.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
